questions: (1) "Does, and to what extent, the presence of SCI decrease the risk of prostate cancer with respect to the general population?" and (2) "Is there any statistically significant difference in PSA levels between males with SCI and their able-bodied age-matched controls?"
MATERIALS AND METHODS
The study was conducted according to the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement; 19 it also complies with the guidelines for Meta-Analyses and Systematic Reviews of Observational Studies (MOOSE). 20 PRISMA and MOOSE Checklists have been presented as Supplementary Table 1 and 2. The International prospective register of systematic reviews (PROSPERO) registration number is CRD42017057672.
Systematic search strategy
We conducted a systematic search in MEDLINE, Cochrane Library, Scopus, CINAHL, and ScienceDirect to identify all relevant studies in English language with the terms: ("spinal cord injur*" OR "spine injur*" OR "spinal injur*" OR paraplegia OR tetraplegia OR quadriplegia) AND (prostate OR "prostate specific antigen" OR PSA OR "prostate tumour" OR "prostate neoplasm" OR "prostate adenocarcinoma"). If it was not clear from title and abstract whether the paper contained relevant data, the full paper was retrieved. The references cited in all full-text articles were also hand-searched in an effort to obtain additional studies for inclusion.
Inclusion and exclusion criteria
The primary outcome of interest was the relationship between SCI and prostate cancer. The secondary outcome was the difference in serum PSA levels between males with SCI and able-bodied subjects. The eligibility criteria used for the study were: (1) observational case-control studies, enrolling individuals aged 18 years or older having SCI and an able-bodied control group; (2) availability of odds ratios (ORs) for prostate cancer or data for its calculation and/or mean ± standard deviation (s.d.) of PSA levels in both groups. Two independent reviewers (AB and SDA) assessed the eligibility of each selected paper; any disagreement was resolved via discussion involving a third reviewer (FF).
Data extraction
Data were extracted from the selected articles by including the first author, publication year, geographic region, and mean age of participants. From the studies evaluating prostate cancer, we extracted the number of events (prostate cancer) and the total number of participants in cases (males with SCI) and controls (age-matched able-bodied subjects); from the studies reporting PSA levels, we obtained mean ± s.d. of PSA measurement along with the total number of participants in cases and controls. Where data were missing or inconsistent, the authors were contacted to obtain the necessary information.
Quality assessment
The quality of studies was assessed through the "star system" of the Newcastle-Ottawa Quality Assessment Scale (NOS). 21 The minimum number of stars was 0 and the maximum that could be awarded was 9 stars. Those getting scores ≥7 were regarded as high-quality studies. The quality assessment was performed by two reviewers (AB and FF). Any disagreement was resolved by a third author (SF) who reevaluated the original study.
Statistical analysis
The relationship between SCI and prostate cancer was assessed using OR and 95% confidence interval (95% CI) as well as by Mantel-Haenszel estimates. The differences in PSA levels were assessed by calculating the standardized mean difference (SMD). In the presence of significant heterogeneity, data were combined using random effects models, which assumed that the included studies have varying effect sizes, thus providing a conservative estimate of the overall effect. For nonsignificant heterogeneity, the results were pooled in a fixed effects model. The Cochran's Chi-square (Cochran's Q) test and the I 2 test were carried out to analyze statistical heterogeneity between the results of different studies. I 2 <25% was considered as no heterogeneity, whereas I 2 >50% and/or P < 0.05 indicated substantial heterogeneity. In order to illustrate heterogeneity that may not be fully conveyed by 95% CI, 95% prediction intervals were also included in the summary results of random effects models, as previously reported. 22 Meta-regression and subgroup analyses were conducted to investigate between-study heterogeneity, by taking into account covariates that could affect the estimates. In particular, predictors which might be potential sources of heterogeneity, such as publication year, geographic region, NOS quality score of the studies, sample size, and mean age of the participants, were included in linear meta-regression models where the regression coefficient () described how the outcome variable (the estimate) changed with a unit increase in the explanatory variable (the potential effect modifier). Publication bias was graphically identified using funnel plots.
The extracted data were analyzed using the R statistical software ( 
RESULTS

Study selection and quality assessment
The electronic search yielded 1159 studies. Three articles were retrieved from the manual search. After removal of duplicate, 839 studies were left, 802 of which were excluded as they were irrelevant on the basis of titles and abstracts. Hence, as shown in Figure 1 , a total of 37 studies were identified; however, only 9 of them met the inclusion criteria. 12, 13, [16] [17] [18] [23] [24] [25] [26] The details of the selected articles are reported in Table 1 .
Five studies evaluated the difference in the prevalence of prostate cancer between males with SCI and able-bodied controls. 12, [16] [17] [18] 26 In all the studies, the included males were diagnosed with prostate cancer after they sustained SCI. Six studies reported serum PSA levels between the two groups of subjects. 13, 16, 17, [23] [24] [25] Quality rating of the studies, based on the NOS score, is outlined in Table 2 . Quality scores ranged from 5 to 8. Eight articles were considered to be of high quality, 12, 13, [16] [17] [18] [24] [25] [26] scoring ≥7; one article was assessed to be moderate. 23 In the study by Lynne et al. 23 a selection bias could not be ruled out since that study enrolled only volunteers and comparability could not be ensured by adjusting either on age or other variables.
Synthesis of results
Overall, five studies evaluating the risk of prostate cancer 12, [16] [17] [18] 26 provided information on 35 293 males with SCI and 158 140 able-bodied controls. As shown in Figure 2a , pooled OR suggested that the presence of SCI reduces the risk of prostate cancer by almost one-half as compared to that in able-bodied males (OR = 0.47, 95% CI: 0.27 to 0.83, P = 0.009). Between-study heterogeneity was revealed by I 2 value >50% (P for heterogeneity = 0.06, I 2 = 56%). The six studies that reported PSA levels 13, 16, 17, [23] [24] [25] provided information on 391 males with SCI and 1921 able-bodied controls. As shown in Figure 2b , the overall difference between the two groups was not found to be statistically significant (pooled SMD: 0.11, 95% CI: −0.46 to 0.68, P = 0.7; P for heterogeneity < 0.00001, I 2 = 95%).
Publication bias and heterogeneity evaluation
As shown in Figure 3a , the reasonably symmetrical shape of funnel plot suggested the absence of obvious publication bias among studies investigating the risk of prostate cancer. On the contrary, a clear asymmetry was observed in the funnel plot of studies analyzing PSA levels ( Figure 3b) . As between-study heterogeneity in the pooled analyses was found (Figure 2) , linear meta-regression analyses were performed in order to detect possible covariates responsible for this variability.
It was observed that only the mean age of study population contributed significantly to the source of heterogeneity in the analysis of prostate cancer: the older age of the participants was significantly associated with a higher decrease in OR for prostate cancer in SCI as compared to the controls ( = −0.10; 95% CI: −0.19 to −0.01; P = 0.02). Accordingly, in a subgroup analysis (Figure 4a) , where we excluded the study by Torricelli et al. 17 and the largest study by Lee et al. 12 both reporting a mean age of participants to be <55 years, the pooled OR for the association between SCI and prostate cancer further decreased up to 0.35 (95% CI: 0.22 to 0.56, P < 0.0001) with no heterogeneity (P for heterogeneity = 0.33, I 2 = 9%). As far as PSA levels were concerned, in the linear meta-regression models, both sample size and NOS quality score of the studies contributed significantly to heterogeneity: lower values of SMD, indicative of lower PSA levels in SCI as compared to that in controls, were associated with a higher NOS quality score ( = −1.48; 95% CI: −1.92 to −1.04; P < 0.0001) and a larger sample size of the study population ( = −0.03; 95% CI: −0.06 to −0.001; P = 0.03). In a subgroup analysis (Figure 4b) , where we excluded the study by The PSA values reported by Scott et al. 18 were not included in the meta-analysis as they were measured only in men with a diagnosis of prostate cancer. EIA: enzyme immunoassay; NA: not available; PSA: prostate-specific antigen; SCI: spinal cord injury; C: cervical; T: thoracic; LS: lumbosacral; T12: twelfth thoracic vertebra; L1: first lumbar vertebra Lynne et al. 23 exhibiting both the lowest NOS score (Table 1 ) and the smallest sample size, the pooled SMD indicated lower PSA levels in SCI, which, however, were not statistically significant (SMD: −0.36; 95% CI: -0.74 to 0.02, P = 0.07) and associated with the persistence of large heterogeneity (P for heterogeneity < 0.00001, I 2 = 89%).
DISCUSSION
Although a lower risk of prostate cancer has been reported among males with SCI as compared to the able-bodied age-matched individuals, the actual decrease in its prevalence within this population has not yet been determined. The results from the present meta-analysis of five carefully selected observational case-control studies 12, [16] [17] [18] 26 suggest that the presence of SCI reduces the risk of prostate cancer by almost one-half as compared to their able-bodied age-matched subjects. Indeed, according to the results of the meta-regression models, when the analysis was restricted to males of mean age over 55 years, the risk decreased up to 65% than that in the controls, with a true population effect size between 44% and 78% (P < 0.0001), indicating that, as the prevalence of prostate cancer increases with an increase in the age of the general population, the "protective" effect of SCI becomes more evident.
The interruption of neural pathways to the prostate has been suggested to be a possible mechanism underlying the lower risk of prostate cancer in individuals with SCI. 10 In rats, where autonomic nervous system plays a key role in the growth of the prostate gland, 27 prostate denervation promotes changes in the cellular morphology, growth, and functions of the gland. 28 However, in humans, the influence of neurologic factors on the physiology/pathophysiology of the prostate remains largely unknown. Nevertheless, an increased risk of prostate cancer in paraplegic male subjects as compared to that in tetraplegic patients has been reported in two studies, 12, 29 which supports the role of denervation in lowering the incidence of prostate cancer after SCI. A further and even more relevant role would be played by androgen deficiency, peculiar to this population. High rates of biochemical androgen deficiency, ranging from approximately 33% to 46%, have been reported in males having chronic SCI. [5] [6] [7] [8] [9] Whether and to what extent it can result in clinical hypogonadism is still unclear, because in the presence of SCI, the sexual symptoms, along with other putative clinical features of hypogonadism (e.g., changes in body composition, osteoporosis, anemia, and mood disorders), overlap with direct or indirect consequences of neurological damage and disability. However, regardless of other putative clinical reflections, androgen deficiency could prove to be protective to some extent, resulting in a lower incidence of prostate cancer. Evidence shows that both the occurrence and progression of prostate cancer are influenced by androgens as (1) prolonged administration of high dosages of testosterone induces prostate cancer in rats, (2) malignancies of the prostate rarely occur in dogs and men castrated prior to puberty, and (3) androgen-ablative therapy inhibits the growth of prostate tumor. 30 In keeping with the notion of a major role of androgens in prostate cancer, meta-analyses indicate that shorter polymorphic cytosine-adenine-guanine (CAG) repeat sequences in the androgen receptor gene, which promote both a higher receptor binding affinity for androgens and a higher transactivation activity, are associated with an increased risk of prostate cancer. 31, 32 In the present analysis, a poor value of serum PSA levels as a screening tool for prostate cancer following SCI resulted from the large heterogeneity between the included studies that reported its circulating levels in males with SCI and able-bodied controls (Figure 2b) . In the crude analysis, although the overall difference between the two groups was not statistically significant, PSA levels were higher in SCI group. On the contrary, when, according to the results of the meta-regression models, the subgroup analysis was restricted to studies exhibiting both the highest NOS quality score and the largest sample size, the pooled estimate indicated lower PSA levels in SCI, which, however, were not statistically significant and showed persistent large heterogeneity (Figure 4b) . Lower PSA levels in males with SCI would be in line with the low prostate volume, which has repeatedly been reported in this population. [13] [14] [15] [16] [17] Possibly, androgen deficiency and/or prostate denervation counteract the opposite impact of chronic inflammation, catheterization, and repeated manual bowel evacuation on prostate physiology/pathophysiology. Some limitations of this meta-analysis have been recognized. Firstly, the inclusion of a limited number of studies. This, however, resulted from a strict screening and selection of the literature. Although only five studies were included in the quantitative analysis of prostate cancer, as a whole, they provided information on a very large number of males with SCI and their age-matched able-bodied controls. The study by Lee et al. 12 accounted for the largest proportion of the global study population; nevertheless, when this study, where the mean age was below 55 years, was excluded, according to the results of the meta-regression models, the pooled estimate remained statistically significant, with a further decrease (up to 65%) in the risk of prostate cancer in males with SCI as compared to that in their controls. Secondly, the availability of a limited number of studies refrained the authors from performing multivariable meta-regression analyses that would have helped detect possible independent associations of the different covariates with the estimates. A further limitation of this meta-analysis is that in the selected studies, information on the key factors having a potential impact on the pathophysiology of the prostate was largely incomplete. In particular, the lack of data on variables which can exert opposite effects on prostate growth and PSA levels in SCI (on the one hand, testosterone levels and the level of the lesion; on the other hand, chronic prostate inflammation, catheterization, and repeated manual bowel evacuation) did not let the authors explain, by meta-regression analyses, their significance in contributing to the between-study heterogeneity in PSA levels. For instance, only the study by Bartoletti et al. 16 reported testosterone levels in 113 males with SCI and 109 age-matched able-bodied subjects; although the SCI group showed significantly lower testosterone levels, PSA values, prostate sizes, and prostate cancer prevalence, the independent association of testosterone with prostate endpoints was not investigated by multivariable regression models.
On the basis of the present study, it can be concluded that, in older males, chronic SCI represents a condition which reduces the risk of prostate cancer up to 65% as compared to that in able-bodied controls. The large between-study heterogeneity on serum PSA levels makes this marker a poor reliable screening tool for prostate cancer following SCI. This was mainly due to the interaction of opposite effects exerted by clinical variables peculiar to this population. These findings should be considered in defining more appropriate screening strategies for prostate cancer in males with SCI.
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